Key points are not available for this paper at this time.
We herein explored the correlation between the triglyceride-glucose index (TyGI) and hyperuricemia (HUA) in patients with type 2 diabetes (T2DM). Patients with T2DM who visited the Metabolic Disease Management Center (MMC) of Tianjin Fourth Central Hospital from October 2017 to August 2024 were selected as our study subjects. We measured fasting plasma glucose (FPG), triglyceride (TG), serum uric acid (SUA), and glycated hemoglobin levels (HbA1c); calculated the TyGI; and initially conducted a cross-sectional study to analyze the association between TyGI and HUA. A two-year retrospective cohort study was subsequently performed to further investigate the correlation between TyGI and the risk of developing HUA, and its resolution. A total of 11,806 patients were included, with 6,759 completing SUA tests. Of these patients, 1,270 patients (18.8%) manifested concurrent HUA; and 46.6% were newly diagnosed cases. Spearman correlation analysis revealed a significant positive correlation between TyGI and SUA levels in 4,520 T2DM patients who had not taken uric acid-lowering drugs in the previous month (r = 0.23, p < 0.001). Logistic regression analysis indicated that maleness, obesity, smoking, and high TyGI (OR = 1.95, p < 0.001) were significantly associated with HUA. In a two-year retrospective cohort follow-up of 1,074 patients without HUA, 154 patients (14.3%) developed HUA; and COX regression analysis identified male sex, obesity, and a high TyGI during follow-up (OR = 2.087, p < 0.001) as significant risk factors. Additionally, a retrospective follow-up of 172 patients newly diagnosed with HUA revealed that SUA levels returned to normal within two years in 71 patients (41.3%). COX regression analysis further suggested that low TyGI during follow-up (OR = 1.936, p = 0.041) and the use of sodium–glucose cotransporter 2 inhibitors (SGLT2i) medications (OR = 1.856, p = 0.047) contributed to the normalization of SUA levels. Obesity and higher TyGI promoted the development of HUA in T2DM patients, while lower TyGI and the use of SGLT2i medications appeared to facilitate the restoration of SUA to normal levels in patients with HUA. Our finding provide new insights into the clinical management of HUA with respect to its prevention and treatment in T2DM patients.
Xia et al. (Sat,) studied this question.